Newsroom
AbelZeta Announces Formation of Scientific Advisory Board to Support Inflammatory and Immunological Diseases
Abelzeta announced the formation of a Scientific Advisory Board (the “SAB”) to advance its cell therapies for the treatment of inflammatory and immunological diseases.
AbelZeta to Present at the Annual J.P. Morgan Healthcare Conference
Abelzeta announced that Tony (Bizuo) Liu, Chairman and CEO, will present an update on the Company at the 42nd Annual J.P. Morgan Healthcare Conference on January 10, 2024.
AbelZeta Announces Amendment to Worldwide Collaboration and License Agreement with Janssen to Include China
Amended worldwide collaboration and license agreement for CD20-directed chimeric antigen receptor T (CAR-T) C-CAR039 and C-CAR066 to include an option for commercialization of products in China.
AbelZeta Presents Data from Two Clinical Studies Relating to its Immuno-Oncology Drug Development at the 65th ASH Annual Meeting
AbelZeta Pharma, Inc. presented clinical data for both C-CAR039 for the treatment of patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL), and C-CAR066, for the treatment of patients with r/r large B-cell lymphoma (LBCL) who failed prior CD19 CAR-T therapy at the 65th American Society of Hematology (ASH) Annual Meeting.
AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3) Armored CAR-T Therapy in China
ROCKVILLE, MD and SHANGHAI, China, December 7, 2023 – AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer, inflammatory and immunological diseases, today announced an agreement with AstraZeneca to co-develop C-CAR031, an autologous, armored GPC3-targeting chimeric antigen receptor T Cells (CAR-T) therapy, in hepatocellular carcinoma (HCC).
AbelZeta Announces Two Abstracts Accepted for Presentation at the 65th ASH Annual Meeting
AbelZeta Pharma, Inc. (“AbelZeta” or the “Company”), a global clinical-stage biopharmaceutical company focused on discovery and development of innovative and proprietary cell-based therapeutic products, announced today that two abstracts relating to its immuno-oncology drug development have been accepted for presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held in San Diego, California, and online from December 9 to 12, 2023.
CBMG Holdings Announces Name Change to AbelZeta Pharma, Inc.
CBMG Holdings (the “Company”) today announced that following the spin-off of the Company’s stem cell business division, it has changed its name to AbelZeta Pharma, Inc.